Literature DB >> 6136757

Detection of breast carcinoma metastases in bone: relative merits of X-rays and skeletal scintigraphy.

D J Perez, T J Powles, J Milan, J C Gazet, H T Ford, V R McCready, J S MacDonald, R C Coombes.   

Abstract

Of 1116 patients receiving primary treatment for breast carcinoma at the Royal Marsden Hospital since 1976, 651 had an abnormal bone scintigram either at primary diagnosis (378) or on subsequent follow-up (273) and 167 developed radiographically detectable bone metastases (21 at the time of primary diagnosis). Comparison of bone scintigrams and X-rays showed that scintigraphy was an inaccurate localiser of existing radiographic detectable metastases. If X-rays alone are used to detect bone metastases a limited examination with five plates will detect metastases with 92% accuracy. After primary surgery, routine X-ray screening for bone metastases is not necessary since it is possible to identify patients at risk on the basis of clinical examination, chest X-ray, and serum alkaline phosphatase and gamma-glutamyl transpeptidase levels.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6136757     DOI: 10.1016/s0140-6736(83)90692-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  19 in total

1.  Whither the PET scan? The role of PET imaging in the staging and treatment of breast cancer.

Authors:  Alessandra Gennari; Arnoldo Piccardo; Vania Altrinetti; Davide Corradengo; Giampiero Villavecchia; Andrea De Censi
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

2.  Metastatic pancreatic adenocarcinoma presenting as a large pelvic mass mimicking primary osteogenic sarcoma: a series of two patient cases.

Authors:  Nicholas P Webber; Sunil Sharma; Allie H Grossmann; Akram Shaaban; Kevin B Jones; Lester J Layfield; R Lor Randall
Journal:  J Clin Oncol       Date:  2010-08-16       Impact factor: 44.544

3.  Clinical surveillance for early stage breast cancer: an analysis of claims data.

Authors:  M S Simon; M Stano; R K Severson; M S Hoff; D W Smith
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer.

Authors:  Jae Ho Chung; Moo Suk Park; Young Sam Kim; Joon Chang; Joo Hang Kim; Sung Kyu Kim; Se Kyu Kim
Journal:  Yonsei Med J       Date:  2005-06-30       Impact factor: 2.759

5.  Bone metabolic markers in bone metastases.

Authors:  M Koizumi; Y Yamada; T Takiguchi; E Nomura; M Furukawa; T Kitahara; T Yamashita; H Maeda; S Takahashi; K Aiba
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

6.  The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan.

Authors:  Nishikant Avinash Damle; Chandrasekhar Bal; G P Bandopadhyaya; Lalit Kumar; Praveen Kumar; Arun Malhotra; Sneh Lata
Journal:  Jpn J Radiol       Date:  2013-02-02       Impact factor: 2.374

7.  Tests for detecting recurrent disease in the follow-up of patients with breast cancer.

Authors:  J L Mansi; H M Earl; T J Powles; R C Coombes
Journal:  Breast Cancer Res Treat       Date:  1988-07       Impact factor: 4.872

8.  Breast cancer surveillance--a cost-effective strategy.

Authors:  D V Schapira
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

9.  An evaluation of clinical follow-up in women with early stage breast cancer among physician members of the American Society of Clinical Oncology.

Authors:  M S Simon; M Hoff; M Hussein; S Martino; A Walt
Journal:  Breast Cancer Res Treat       Date:  1993-09       Impact factor: 4.872

10.  Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients.

Authors:  Eleni M Karapanagiotou; Evangelos Terpos; Kalliopi D Dilana; Christina Alamara; Ioannis Gkiozos; Aris Polyzos; Kostas N Syrigos
Journal:  Med Oncol       Date:  2009-04-17       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.